Dermatoscopy of "dysplastic nevi": A beacon in diagnostic darkness

European Journal of Dermatology

Volumn 16, Issue 5, 2006, Pages 479-493

  Roesch, Alexander ^a   Burgdorf, Walter ^b   Stolz, Wilhelm ^c   Landthaler, Michael ^a   Vogt, Thomas ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^c Klinikum Schwabing   (Germany)

Author keywords

Dermatoscopy; Dysplastic nevus; Malignant melanoma; Melanocyte 479

Indexed keywords

CELL PROLIFERATION; COMPUTER ANALYSIS; DYSPLASTIC NEVUS SYNDROME; EPILUMINESCENCE MICROSCOPY; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; MELANOCYTE; MELANOMA; REVIEW;

DERMATOLOGY; DERMOSCOPY; DIAGNOSIS, DIFFERENTIAL; DYSPLASTIC NEVUS SYNDROME; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MELANOMA; PATHOLOGY; SKIN NEOPLASMS;

EID: 33845243961     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2006.0040     Document Type: Review

References (88)

1. Clark Jr. WH, Elder DE. Guerry Dt, Epstein MN, Greene MH, Van Horn M. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984; 15(12): 1147-65.
2. Elder DE. The dysplastic nevus. Pathology 1985; 17: 291-7.
3. Barnhill RL. Malignant melanoma, dysplastic melanocytic nevi, and Spitz tumors. Histologic classification and characteristics. Clin Plast Surg 2000; 27(3): 331-60; (viii).
4. Clark Jr. WH, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B-K mole syndrome'. Arch Dermatol 1978; 114(5): 732-8.
5. Friedman RJ, Rigel DS, Kopf AW. Early detection of malignant melanoma: the role of physician examination and self-examination of the skin. CA Cancer J Clin 1985; 35(3): 130-51.
6. Hofmann-Wellenhof R, Blum A, Wolf IH, et al. Dermoscopic classification of Clark's nevi (atypical melanocytic nevi). Clin Dermatol 2002; 20(3): 255-8.
7. Ackerman AB. Dysplastic nevus" syndrome: does a survey make it real? J Am Acad Dermatol 2003; 48(3): 461-3.
8. McBride A, Rivers JK, Kopf AW, et al. Clinical features of dysplastic nevi. Dermatol Clin 1991; 9(4): 717-22.
9. Kim JC, Murphy GF. Dysplastic melanocytic nevi and prognostically indeterminate nevomelanomatoid proliferations. Clin Lab Med 2000; 20(4): 691-712.
10. Tucker MA, Fraser MC, Goldstein AM, et al. A natural history of melanomas and dysplastic nevi: an atlas of lesions in melanoma-prone families. Cancer 2002; 94(12): 3192-209.
11. Soyer HP, Massone C, Ferrara G, Argenziano G. Limitations of histopathologic analysis in the recognition of melanoma: a plea for a combined diagnostic approach of histopathologic and dermoscopic evaluation. Arch Dermatol 2005; 141(2): 209-11.
12. Cho KR, Vogelstein B. Genetic alterations in the adenomacarcinoma sequence. Cancer 1992; 70(6 Suppl): 1727-31.
13. Rudolph P. The dysplastic nevus. An Ariadne's thread through a conceptual labyrinth. Pathologe 2002; 23(2): 128-34.
14. Ackerman AB. What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 1988; 13(3): 241-56.
15. Kerl H, Soyer HP, Cerroni L, Wolf IH, Ackerman AB. Ancient melanocytic nevus. Semin Diagn Pathol 1998; 15(3): 210-5.
16. Tronnier M, Garbe C, Brocker EB, et al. Standards in histopathologic diagnosis of malignant melanomas. Recommendations of the Working Group of the Central Malignant Melanoma Registry of the German Dermatologic Society. Hautarzt 1997; 48(10): 720-9.
17. Ackerman AB, Cerroni L, Kerl H. Pitfalls in histopathologic diagnosis of malignant melanoma. Philadelphia, Baltimore, Hong Kong, Munich, Sydney, Tokyo: Lea and Febiger, 1994.
18. Barnhill RL. Tumors of melanocytes. In: Barnhill RL, ed. Textbook of Dermatopathology. 1998: 537-91; (New York).
19. Barnhill RL, Roush GC, Duray PH. Correlation of histologic architectural and cytoplasmic features with nuclear atypia in atypical (dysplastic) nevomelanocytic nevi. Hum Pathol 1990; 21(1): 51-8.
20. Duncan LM, Berwick M, Bruijn JA, Byers HR, Mihm MC, Barnhill RL. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993; 100(3): 318S-321S.
21. Cramer S. Interobserver variability in surgical pathology. Adv Pathol 1996; 9: 3.
22. In: Stolz W, Braun-Falco O, Bilek P, Burgdorf WHC, Landthaler M, eds. Color Atlas of Dermatoscopy. 2nd ed. Berlin, Germany: Blackwell, 2002.
23. Stolz W, Schmoeckel C, Landthaler M, Braun-Falco O. Association of early malignant melanoma with nevocytic nevi. Cancer 1989; 63(3): 550-5.
24. Harley S, Walsh N. A new look at nevus-associated melanomas. Am J Dermatopathol 1996; 18(2): 137-41.
25. Nordlund JJ, Kirkwood J, Forget BM, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985; 45(4): 1855-61.
26. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987; 17(3): 459-68.
27. MacKie RM, Freudenberger T, Aitchison TC. Personal risk-factor chart for cutaneous melanoma. Lancet 1989; 2(8661): 487-90.
28. Augustsson A, Stierner U, Rosdahl I, Suurkula M. Common and dysplastic naevi as risk factors for cutaneous malignant melanoma in a Swedish population. Acta Derm Venereol 1991; 71(6): 518-24.
29. Grob JJ, Gouvernet J, Aymar D, et al. Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990; 66(2): 387-95.
30. Halpern AC, Guerry D, Elder DE, et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study Arch Dermatol 1991; 127(7): 995-9.
31. Garbe C, Buttner P, Weiss J, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the Central Malignant Melanoma Registry of the German Dermatological Society. J Invest Dermatol 1994; 102(5): 695-9.
32. Carli P, Biggeri A, Giannotti B. Malignant melanoma in Italy: risks associated with common and clinically atypical melanocytic nevi. J Am Acad Dermatol 1995; 32(5 Pt 1): 734-9.
33. Grulich AE, Bataille V, Swerdlow AJ, et al. Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia. Int J Cancer 1996; 67(4): 485-91.
34. Bataille V, Bishop JA, Sasieni P, et al. Risk of cutaneous melanoma in relation to the numbers, types and sites of naevi: a case-control study. Br J Cancer 1996; 73(12): 1605-11.
35. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma JAMA 1997; 277(18): 1439-44.
36. Bataille V, Grulich A, Sasieni P, et al. The association between naevi and melanoma in populations with different levels of sun exposure: a joint case-control study of melanoma in the UK and Australia. Br J Cancer 1998; 77(3): 505-10.
37. Rieger E, Soyer HP, Garbe C, et al. Overall and site-specific risk of malignant melanoma associated with nevus counts at different body sites: a multicenter case-control study of the German Central Malignant-Melanoma Registry. Int J Cancer 1995; 62(4): 393-7.
38. Weiss J, Bertz J, Jung EG. Malignant melanoma in southern Germany: different predictive value of risk factors for melanoma subtypes. Dermatologica 1991; 183(2): 109-13.
39. Kanzler MH, Mraz-Gernhard S. Primary cutaneous malignant melanoma and its precursor lesions: diagnostic and therapeutic overview. J Am Acad Dermatol 2001; 45(2): 260-76.
40. Tronnier M, Muller C. Relationship between season and diagnoses of melanocytic tumours. Acta Derm Venereol 2001; 81(2): 112-5.
41. Bale SJ, Dracopoli NC, Tucker MA, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989; 320(21): 1367-72.
42. Goldstein AM, Goldin LR, Dracopoli NC, Clark Jr. WH, Tucker MA. Two-locus linkage analysis of cutaneous malignant melanoma/dysplastic nevi. Am J Hum Genet 1996; 58(5): 1050-6.
43. Fountain JW, Karayiorgou M, Ernstoff MS, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992; 89(21): 10557-61.
44. Cannon-Albright LA, Goldgar DE, Meyer LJ, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992; 258(5085): 1148-52.
45. Lee JY, Dong SM, Shin MS, et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus. Biochem Biophys Res Commun 1997; 237(3): 667-72.
46. Park WS, Vortmeyer AO, Pack S, et al. Allelic deletion at chromosome 9p21(p16) and 17p13(p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998; 29(2): 127-30.
47. Boni R, Zhuang Z, Albuquerque A, Vortmeyer A, Duray P. Loss of heterozygosity detected on 1p and 9q in microdissected atypical nevi. Arch Dermatol 1998; 134(7): 882-3.
48. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol 2000; 42(5 Pt 1): 705-22; (quiz 723-6).
49. Healy E, Sikkink S, Rees JL. Infrequent mutation of p16INK4 in sporadic melanoma. J Invest Dermatol 1996; 107(3): 318-21.
50. Papp T, Pemsel H, Zimmermann R, Bastrop R, Weiss DG, Schiffmann D. Mutational analysis of the N-ras, p53, p16INK4a, CDK4, and MC1R genes in human congenital melanocytic naevi. J Med Genet 1999; 36(8): 610-4.
51. Levin DB, Wilson K, Valadares de Amorim G, Webber J, Kenny P, Kusser W. Detection of p53 mutations in benign and dysplastic nevi. Cancer Res 1995; 55(19): 4278-82.
52. Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W. p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. Histopathology 1997; 30(1): 57-63.
53. Cristofolini M, Boi S, Girlando S, et al. p53 Protein expression in nevi and melanomas. Arch Dermatol 1993; 129(6): 739-43.
54. Hussein MR, Roggero E, Sudilovsky EC, Tuthill RJ, Wood GS, Sudilovsky O. Alterations of mismatch repair protein expression in benign melanocytic nevi, melanocytic dysplastic nevi, and cutaneous malignant melanomas. Am J Dermatopatnol 2001; 23(4): 308-14.
55. Hussein MR, Sun M, Tuthill RJ, et al. Comprehensive analysis of 112 melanocytic skin lesions demonstrates microsatellite instability in melanomas and dysplastic nevi, but not in benign nevi. J Cutan Pathol 2001; 28(7): 343-50.
56. Birindelli S, Tragni G, Bartoli C, et al. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma. Int J Cancer 2000; 86(2): 255-61.
57. Shukla VK, Hughes DC, Hughes LE, McCormick F, Padua RA. ras mutations in human melanotic lesions: K-ras activation is a frequent and early event in melanoma development. Oncogene Res 1989; 5(2): 121-7.
58. Van Duinen CM, Fleuren GJ, Bruijn JA. The extracellular matrix in pigmented skin lesions: an immunohistochemical study. Histopathology 1994; 24(1): 33-40.
59. Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994; 144(2): 329-36.
60. Pollock PM, Harper UL, Hansen KS, et al. High frequency of BRAF mutations in nevi. Nat Genet 2003; 33(1): 19-20.
61. Glaessl A, Bosserhoff AK, Buettner R, Hohenleutner U, Landthaler M, Stolz W. Increase in telomerase activity during progression of melanocytic cells from melanocytic naevi to malignant melanomas. Arch Dermatol Res 1999; 291(2-3): 81-7.
62. Miracco C, Pacenti L, Santopietro R, Laurini L, Biagioli M, Luzi P. Evaluation of telomerase activity in cutaneous melanocytic proliferations. Hum Pathol 2000; 31(9): 1018-21.
63. Rudolph P, Schubert C, Tamm S, et al. Telomerase activity in melanocytic lesions: A potential marker of tumor biology. Am J Pathol 2000; 156(4): 1425-32.
64. Hussein MR, Wood GS. Molecular aspects of melanocytic dysplastic nevi. J Mol Diagn 2002; 4(2): 71-80.
65. Herlyn M, Satyamoorthy K. Melanoma. In: DeVita V, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. Philadelphia, USA: Lippincott-Raven Publishers, 2000: 2003-12.
66. Wachsmuth RC, Harland M, Bishop JA. The atypical-mole syndrome and predisposition to melanoma. N Engl J Med 1998; 339(5): 348-9.
67. Rhodes AR, Harrist TJ, Day CL, Mihm Jr. MC, Fitzpatrick TB, Sober AJ. Dysplastic melanocytic nevi in histologic association with 234 primary cutaneous melanomas. J Am Acad Dermatol 1983; 9(4): 563-74.
68. Tsao H, Zhang X, Majewski P, Haluska FG. Mutational and expression analysis of the p73 gene in melanoma cell lines. Cancer Res 1999; 59(1): 172-4.
69. Richetta A, Silipo V, Calvieri S, et al. Microsatellite instability in primary and metastatic melanoma. J Invest Dermatol 1997; 109(1): 119-20.
70. Kroiss MM, Vogt TM, Schlegel J, Landthaler M, Stolz W. Microsatellite instability in malignant melanomas. Acta Derm Venereol 2001; 81(4): 242-5.
71. Becker B, Roesch A, Hafner C, et al. Discrimination of melanocytic tumors by cDNA array hybridization of tissues prepared by laser pressure catapulting. J Invest Dermatol 2004; 122(2): 361-8.
72. Roesch A, Vogt T, Stolz W, Dugas M, Landthaler M, Becker B. Discrimination between gene expression patterns in the invasive margin and the tumour core of malignant melanomas. Melanoma Res 2003; 13(5): 503-9.
73. Vogl A, Sartorius U, Vogt T, et al. Gene Expression Profile Changes between Melanoma Metastases and their Daughter Cell Lines: Implication for Vaccination Protocols. J Invest Dermatol 2005; 124(2): 401-4.
74. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406(6795): 536-40.
75. Davis Jr. RL, DuBreuil RM, Reddy SP, Dooley TP. Methods for gene expression profiling in dermatology research using DermArray nylon filter DNA microarrays. Methods Mol Biol 2005; 289: 399-412.
76. Baldi A, Battista T, De Luca A, et al. Identification of genes down-regulated during melanoma progression: a cDNA array study. Exp Dermatol 2003; 12(2): 213-8.
77. Mirmohammadsadegh A, Baer A, Nambiar S, Bardenheuer W, Hengge UR. Rapid identification of dysregulated genes in cutaneous malignant melanoma metastases using cDNA technology. Cells Tissues Organs 2004; 177(3): 119-23.
78. Skvara H, Teban L, Fiebiger M, Binder M, Kittler H. Limitations of dermoscopy in the recognition of melanoma. Arch Dermatol 2005; 141(2): 155-60.
79. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. N Engl J Med 2003; 349(23): 2233-40.
80. Argenziano G, Soyer HP, Chimenti S, et al. Dermoscopy of pigmented skin lesions: results of a consensus meeting via the Internet. J Am Acad Dermatol 2003; 48(5): 679-93.
81. Argenziano G, Fabbrocini G, Carli P, De Giorgi V, Sammarco E, Delfino M. Epiluminescence microscopy for the diagnosis of doubtful melanocytic skin lesions. Comparison of the ABCD rule of dermatoscopy and a new 7-point checklist based on pattern analysis. Arch Dermatol 1998; 134(12): 1563-70.
82. Nachbar F, Stolz W, Merkle T, et al. The ABCD rule of dermatoscopy. High prospective value in the diagnosis of doubtful melanocytic skin lesions. J Am Acad Dermatol 1994; 30(4): 551-9.
83. Stolz W. ABCD rule of dermatoscopy: a new practical method for early recognition of malignant melanoma. Eur J Dermatol 1994; 4: 521-7.
84. Stolz W, Riemann A, Cognetta AB, Pillet L. ABCD rule of dermatoscopy: a new practical method for early recognition of malignant melanoma. Eur J Dermatol 1994; 4: 521-7.
85. Binder M, Schwarz M, Winkler A, et al. Epiluminescence microscopy. A useful tool for the diagnosis of pigmented skin lesions for formally trained dermatologists. Arch Dermatol 1995; 131(3): 286-91.
86. Menzies SW, Crotty KA, McCarthy WH. The morphologic criteria of the pseudopod in surface microscopy. Arch Dermatol 1995; 131(4): 436-40.
87. Kittler H, Pehamberger H, Wolff K, Binder M. Follow-up of melanocytic skin lesions with digital epiluminescence microscopy: patterns of modifications observed in early melanoma, atypical nevi, and common nevi. J Am Acad Dermatol 2000; 43(3): 467-76.
88. Binder M, Kittler H, Dreiseitl S, Ganster H, Wolff K, Pehamberger H. Computer-aided epiluminescence microscopy of pigmented skin lesions: the value of clinical data for the classification process. Melanoma Res 2000; 10(6): 556-61.